睿智醫藥(300149.SZ):上海睿智與香港理工大學簽署戰略合作框架協議
格隆匯8月12日丨睿智醫藥(300149.SZ)公佈,公司全資子公司上海睿智醫藥研究集團有限公司(以下簡稱“上海睿智”)於近日與香港理工大學(以下簡稱“理大”)簽署了《戰略合作框架協議》,雙方擬探索合作研究的機會,開發用於免疫治療的新型治療藥物。此次合作將結合學術界和醫藥業界的專業知識,以造福癌症患者為長期目標。
理大提供新靶點和學術界的專業知識,上海睿智充分發揮自身的專業優勢,共同合作研發治療藥物。這些藥物被設計用來針對和治療各種形式的癌症。這種合作可以實現從基礎研究到治療藥物開發的無縫過渡,加速將新的癌症治療方法推向市場的過程。此外,此次合作促進了知識和資源共享的環境,這可以使癌症治療進一步地創新和突破。本次合作可以發揮雙方的優勢,推動癌症治療的發展。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.